A Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy

• To describe the management of patients who are receiving myelotoxic chemotherapy including G-CSF use, ESA use, anti-infective use, transfusions and hospitalisations [ Time Frame: The duration of the chemotherapy plus the five years of long term follow up data ] [ Designated as safety issue: No ]
• To describe toxicities including febrile neutropenia and anemia [ Time Frame: The duration of the chemotherapy ] [ Designated as safety issue: No ]

This is a multi center international observational study of subjects receiving myelotoxic regimens, with an investigator assessed risk of Febrile Neutropenia (FN) ≥ 20%, for the treatment of solid tumors (breast, ovarian and lung). Approximately 100-150 sites will contribute information on 10-15 subjects treated at their institution.

This is a multi center international observational study of subjects receiving myelotoxic regimens, with an investigator assessed risk of FN ≥ 20%, for the treatment of solid tumors (breast, ovarian and lung). Approximately 100-150 sites will contribute information on 10-15 subjects treated at their institution. Sites will be selected where the data specified below is routinely collected for patient management. The selection of sites will be managed to try and represent a selection of various treating centers within each country. However, whilst sites will be encouraged to provide data on patients with all tumor types this will not be enforced and sites or indeed countries may enroll patients to only 1 tumor group. The reason for any site not wishing to participate will be recorded and reported at study end. Approximately 1300 subjects will be recruited . The aim is to have approximately 800 breast cancer, 300 Non-Small Cell Lung Cancer, 100 Small-Cell Lung Cancer and 100 ovarian cancer subjects.

Subjects greater than or equal to 18 years old. Subjects with breast, ovarian or lung cancer. Subjects receiving chemotherapy in any schedule, e.g. dose dense or standard chemotherapy.

Subjects with Investigator assessed risk of febrile neutropenia (FN) ≥20% (based on 2006 European Organisation for Research and Treatment of Cancer (EORTC) G-CSF Guidelines).

Subjects with concurrent administration of radiotherapy are not eligible (previous radiotherapy is permitted if terminated at least 2 weeks prior to commencing applicable chemotherapy in this study).

Written subject consent (where required by local law).

• Breast Cancer
• Non-Small Cell Lung Cancer
• Ovarian Cancer
• Small Cell Lung Cancer

Inclusion Criteria:

• Subjects greater than or equal to 18 years old with breast, ovarian or lung cancer receiving chemotherapy in any schedule, e.g. dose dense or standard chemotherapy.
• These subjects must have an Investigator assessed risk of febrile neutropenia (FN) ≥20% (based on 2006 EORTC G-CSF Guidelines

Exclusion Criteria:

- Subjects with concurrent administration of radiotherapy are not eligible (previous radiotherapy is permitted if terminated at least 2 weeks prior to commencing applicable chemotherapy in this study).